SLE Treatments

To evaluate the efficacy and safety of the calcineurin inhibitors (CNIs) cyclosporine (CyA) and tacrolimus…

Calcineurin inhibitors, like Cyclosporin and Tacrolimus, target T-cells.

Treatment of moderate to severe systemic lupus erythematosus with epratuzumab infusions was…

Epratuzumab targets B-cells.

Objectives The efficacy and safety of sifalimumab were assessed in a phase IIb, randomised, double-blind, placebo-controlled study (NCT01283139) of adults with moderate to severe active systemic lupus erythematosus (SLE).

Sifalimumab targets interferon-α of the innate immune response. It is anticipated to be the next big thing in Lupus treatment.

Patients had refractory disease, and were followed for up to 14 years

Rituximab must be the most widely used drug for Lupus that has failed all clinical trials in Lupus. In fact, it is the go-to drug in SLE when all else fails (short of ablative chemotherapy with haemopoietic stem cell rescue).
Obviously, 100% of rheumatologists can’t be wrong. We blame trial design for the trial failure, obviously. Our esteemed clinical acumen trumps evidence-based medicine, anytime.
This is not said tongue-in-cheek: 100% of rheumatologists believe so. Is it any wonder then that 99% of treatment in Rheumatology is “off-label”?